Press releases

03 September 2024 – Ebola: a study in Guinea reveals persistent immunity five years after vaccination

13 January 2020 – PREVAC-UP: The Partnership for research on Ebola Vaccination extends follow-up and builds research capacity against deadly disease

Publications

PREVAC-UP:

Wiedemann, A., et al. Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases. Nat Commun, 2024-15, 7666.

Lhomme, E., et al., Projet PREVAC-UP : la recherche clinique vaccinale contre Ebola comme levier de la coopération inter-universitaire et du renforcement des capacités en Guinée. Revue d’Épidémiologie et de Santé Publique, 2023. 71: p. 102002.

PREVAC Study Team, Randomized Trial of Vaccines for Zaire Ebola Virus Disease. New England Journal of Medicine, 2022-12-14. 387(26).

Baiden, F., et al., Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols. PLOS ONE, 2022. 17(7): p. e0270968.

PREVAC:

Badio, M., et al., Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials, 2021. 22(1): p. 86.

Dada, S., et al., Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R’s). BMC Public Health, 2019. 19(1): p. 1665.

Lhomme, E., et al., Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context. Trials, 2019. 20(1): p. 422.

Faye, S.L.B., et al., Engager (avec) les communautés dans un essai vaccinal en contexte post-Ebola (Guinée Conakry) : un modèle basé sur les « champions ». Sciences & Actions Sociales, 2018. 10(2): p. 112-141.

PREVAC-UP project is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme supported by the European Union. PREVAC-UP also benefits from co-funding from Inserm, the NIAID, the LSHTM and the COMAHS as well as host country support from Liberia, Sierra Leone, Guinea and Mali.